Effects of menopause and estrogen replacement therapy or hormone replacement therapy in women with diabetes mellitus: Consensus opinion of The North American Menopause Society

Menopause

Volumn 7, Issue 2, 2000, Pages 87-95

  Dunaif, Andrea ^a   Utian, Wulf H ^a   Brandenburg, Suzanne L ^a   Gerhard, Marie ^a   Lobo, Rogerio A ^a   Solomon, Caren G ^a   Sowers, James R ^a  

^a NAMS   (United States)

Author keywords

Cardiovascular risk factors; Estrogen replacement therapy; Hormone replacement therapy; Menopause; Type 2 diabetes mellitus

Indexed keywords

ESTROGEN; GESTAGEN; PROGESTERONE;

ADULT; CARDIOVASCULAR RISK; ESTROGEN THERAPY; FEMALE; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL SOCIETY; MENOPAUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0034015166     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200007020-00004     Document Type: Review

References (87)

1. Boggs PP, Utian WH. The North American Menopause Society develops consensus opinions. Menopause 1998;5:67-8 (editorial).
2. Achieving long-term continuance of menopausal ERT/HRT: consensus opinion of The North American Menopause Society. Menopause 1998;5:69-76.
3. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
4. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
5. Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991;164:489-94.
6. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991;325:756-62.
7. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
8. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-24.
9. Sowers JR. Obesity and cardiovascular disease. Clin Chem 1998;44:1821-5.
10. Peiris AN, Struve MF, Mueller RA, Lee MB, Kissebah AH. Glucose metabolism in obesity: influence of fat distribution. J Clin Endocrinol Metab 1988;67:760-7.
11. Stevenson JC. Metabolic effects of the menopause and oestrogen replacement. Bailliere's Clin Obstet Gynaecol 1996;10:449-67.
12. Gaspar UJ, Gotta JM, van den Brule FA. Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects. Maturitas 1995;21:171-8.
13. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, Courie CC, Beiber G, Boyko E, Stern M, Bennet P, eds. Diabetes in America, 2nd ed. (NIH Publication No. 95-1468). Washington, DC: US Government Printing Office, 1995.
14. Goldberg RJ, Larson M, Levy D. Factors associated with survival to 75 years of age in middle-aged men and women. The Framingham Study. Arch Intern Med 1996;156:505-9.
15. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. JAMA 1979;241:2035-8.
16. Greenland P, Reicher-Reiss H, Goldbourt U, Behar S. In-hospital and 1-year mortality in 1,524 women after myocardial infarction: comparison with 4,315 men. Circulation 1991;83:484-91.
17. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265:1861-7.
18. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151:1141-7.
19. Laakso M, Lehto S, Penttila I, Pyorala K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993;88:1421-30.
20. Laakso M. Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes. The Finnish studies. Ann Intern Med 1996;124:127-30.
21. Treatment of hypertension in diabetes. Diabetes Care 1993;16:1394-401.
22. Cowie CC, Howard BV, Harris MI. Serum lipoproteins in African Americans and whites with non-insulin-dependent diabetes in the US population. Circulation 1994;90:1185-93.
23. Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation 1993;87:1135-44.
24. Schumacher M, Weigert S, Wood WG. Do gonadotropins influence serum lipoprotein(a) concentrations? Observations on children, adolescents and adults. Eur J Clin Chem Clin Biochem 1996;34:909-14.
25. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26 year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-77.
26. Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997;103:152-62.
27. Banga JD, Sixma JJ. Diabetes mellitus, vascular disease and thrombosis. Clin Haematol 1986;15:465-92.
28. Jones EW, Mitchell JR. Venous thrombosis in diabetes mellitus. Diabetologia 1983;25:502-5.
29. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997;277:642-5.
30. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-71.
31. Cannon RO III. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem 1998;44(8 Pt 2):1809-19.
32. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998;97:1695-701.
33. Wascher TC, Bachernegg M, Kickenweiz E, et al. Elevation of D-glucose impairs coronary artery autoregulation after slight reduction of coronary flow. Eur J Clin Invest 1995;25:590-4.
34. Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 1998;158:617-21.
35. Lyons TJ. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 1993;71:26B-31B.
36. Hamaty M, Lamberti M, Sowers JR. Diabetic vascular disease and hypertension. Curr Opin Cardiol 1998;13:298-303.
37. O'Mara BA, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: a multisite case-control study. J Chron Dis 1985;38:435-41.
38. Weiderpass E, Gridley G, Persson I, et al. Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer 1997;71:360-3.
39. Haffner SM, Diehl AK, Mitchell DB, Stern MP, Hazuda HP. Increased prevalence of clinical gallbladder disease in subjects with non-insulin-dependent diabetes mellitus. Am J Epidemiol 1990;132:327-35.
40. Franceschi S, la Vecchia C, Negri E, Parazzine F, Boyle P. Breast cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer 1990;26:781-5.
41. Adami HO, McLaughlin J, Ekbom A, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991;2:307-14.
42. van Daele PL, Stolk RP, Burger H, et al. Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam study. Ann Intern Med 1995;122:409-14.
43. Cowie CC, Harris MI, Eberhardt MS. Frequency and determinants of screening for diabetes in the US. Diabetes Care 1994;17:1158-63.
44. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Belle Mead, NY: Exerpta Medica, 1998.
45. Lopez-Lopez R, Huerta R, Malacara JM. Age at menopause in women with type 2 diabetes mellitus. Menopause 1999;6:174-8.
46. American Diabetes Association. Clinical practice recommendations 1999: management of dyslipidemia in adults with diabetes. Diabetes Care 1999;22(Suppl. 1):S1-114.
47. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46.
48. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
49. Utian WH. Determining endometrial pathology in women on HRT. Menopause Management 1998;7(3):7 (editorial).
50. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1999;22(Suppl. 1):S56-9.
51. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
52. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
53. Pan WH, Cedres LB, Liu K, et al. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol 1986;123:504-16.
54. Lehto S, Ronneman T, Haffner SM, Pyorala K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997;46:1354-9.
55. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based anti-hypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996;276:1886-92.
56. Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure. Diabetologia 1996;39:1554-61.
57. UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing the risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-20.
58. Sacks FM, Pfeffer MA, Moye LA, et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
59. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998;98:2513-9.
60. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a sub-group analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.
61. Lewis SZ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998;129:681-9.
62. Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl JMed 1995;333:677-85.
63. Holbrook TL, Barrett-Connor E, Wingard DL. The association of lifetime weight and weight control patterns with diabetes among men and women in an adult community. Int J Obesity 1989;13:723-9.
64. Schneider SH, Vitug A, Ruderman N. Atherosclerosis and physical activity. Diabetes Metab Rev 1986;1:513-53.
65. Stampfer MJ, Colditz GA, Willett WC, Speizer FE, Hennekens CH. A prospective study of moderate alcohol consumption and the risk of coronary heart disease and stroke in women. N Engl J Med 1988;319:267-73.
66. Sereny G, Endrenyi L. Mechanisms and significance of carbohydrate intolerance in chronic alcoholism. Metabolism 1978;27:1041-6.
67. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997;21(Suppl. 1):S5-9.
68. Barnard RJ, Jung T, Inkeles SB. Diet and exercise in the treatment of NIDDM: the need for early emphasis. Diabetes Care 1994;17:1469-72.
69. Trovati M, Carta Q, Cavalot F, et al. Influence of physical training on blood glucose control, glucose tolerance, insulin secretion, and insulin action in non-insulin-dependent diabetic patients. Diabetes Care 1984;7:416-20.
70. Manson JE, Hu FB, Rich-Edwards JW, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999;341:650-8.
71. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
72. Hennekens CH, Peto R, Hutchinson GB, Doll R. An overview of the British and American aspirin studies. N Engl J Med 1988;318:923-4 (letter).
73. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment of Diabetic Retinopathy Study report 14. JAMA 1992;268:1292-300.
74. Gerhard M, Walsh BW, Tawakol A, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1998;98:1158-63.
75. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994;121:936-41.
76. Reis SE, Gloth ST, Blumenthal RS, et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994;89:52-60.
77. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO III. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994;90:786-91.
78. Manson JE, Rimm EB, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann Epidemiol 1992;2:665-73.
79. Tilly-Kiesi M, Kahri J, Pyorala T, et al. Responses of HDL sub-classes, Lp (A-I) and Lp (A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women. Atherosclerosis 1997;129:249-59.
80. Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 1993;60:664-7.
81. Gluek CJ, Lang J, Hamer T, Tracy T. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med 1994;123:59-64.
82. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
83. Skafar DF, Xu R, Morales J, Ram J, Sowers JR. Clinical review 91: female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab 1997;82:3913-8.
84. Miller VM, Vanhoutte PM. Progesterone and modulation of endothelium-dependent responses in canine coronary arteries. Am J Physiol 1991;261(Pt 2):R1022-7.
85. Hanke H, Hanke S, Bruck B, et al. Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis. Atherosclerosis 1996;121:129-38.
86. Hickok LR, Toomey C, Speroff L. A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoprotein levels in postmenopausal women. Obstet Gynecol 1993;82:919-24.
87. Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996;334:1156-62.